# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Despite this headwind, Elanco continues to expect to deliver its full year adjusted EBITDA guidance of $900 million to $940 mil...
Elanco has a long-term supply agreement with TriRx to manufacture select farm animal products at the Speke site. Elanco is work...
TriRx today entered into trading administration, a formal insolvency process in the United Kingdom.
Study Highlights Importance Of Tick Protection As CDC Reports Over 45,000 Human Tickborne Disease Cases Between 2019-2022
Elanco Animal Health (NYSE:ELAN) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0...
2024 Third Quarter(dollars in millions, except per share amounts) Guidance Revenue $1,020to$1,050Reported Net Income $368to...